ClonipresER 0.1 mg

Clonipres is indicated for the following uses, listed by strength of evidence:

Established / approved uses

• Hypertension — oral immediate-release and transdermal patch formulations of Clonipres are approved for management of hypertension, alone or in combination with other antihypertensive agents.
• Attention-Deficit/Hyperactivity Disorder (ADHD) — extended-release oral Clonipres is approved for children and adolescents (6–17 years) as monotherapy or as adjunctive therapy to stimulant medication.
• Severe cancer pain — epidural Clonipres injection is approved, in combination with opioids, for pain in cancer patients not adequately controlled by opioid analgesia alone.

Common off-label uses (evidence-supported but not FDA-approved for this indication)

• Management of symptoms during opioid withdrawal and nicotine/smoking-cessation withdrawal.
• Adjunctive management of alcohol withdrawal symptoms.
• Menopausal vasomotor symptoms (hot flashes), migraine prophylaxis, and tic disorders/Tourette syndrome.
• Severe hypertensive urgency (short-term, under medical supervision).

Use for off-label indications should only occur under a physician's guidance.

Clonidine Hydrochloride (INN) is available as oral tablets commonly in strengths of 100 mcg (0.1 mg) and 200 mcg (0.2 mg), and internationally as a transdermal patch (delivering 0.1, 0.2, or 0.3 mg/24 hours) and as a preservative-free injection for epidural infusion. Each tablet or dosage unit contains Clonidine Hydrochloride as the active pharmaceutical ingredient, along with standard pharmaceutical excipients.

Clonipres is a centrally-acting alpha-2 adrenergic receptor agonist that reduces sympathetic outflow from the central nervous system, lowering blood pressure and heart rate. It is one of the older, well-established antihypertensive agents and is also used, in specific formulations, for attention-deficit/hyperactivity disorder (ADHD) and for severe cancer pain via the epidural route. Clonipres is available as immediate-release tablets, extended-release tablets, a transdermal patch, and an epidural injection, depending on indication and market.

Centrally-acting antihypertensive; Alpha-2 adrenergic agonist

Pharmacodynamics: Clonidine Hydrochloride stimulates central alpha-2 adrenergic receptors, decreasing sympathetic outflow and resulting in reduced peripheral vascular resistance, renal vascular resistance, heart rate, and blood pressure. Central alpha-2 stimulation also underlies its effects on attention/impulsivity (ADHD) and its ability to blunt sympathetic hyperactivity during withdrawal states.

Pharmacokinetics: Oral Clonidine Hydrochloride is well absorbed (bioavailability approximately 75–95%), with peak plasma concentrations reached in about 1–3 hours (immediate-release). It is approximately 20–40% bound to plasma proteins. About half of an absorbed dose is metabolized in the liver; the remainder is excreted unchanged in urine. Elimination half-life is approximately 12–16 hours in patients with normal renal function and may be prolonged up to about 40 hours in severe renal impairment. Transdermal patches provide sustained plasma levels over approximately 7 days.

Clonipres oral tablets may be taken with or without food, at consistent times each day. Extended-release tablets must be swallowed whole and must not be crushed, chewed, or split. The transdermal patch should be applied to a clean, dry, hairless area of intact skin (e.g., upper outer arm or chest) and replaced every 7 days, with the application site rotated. Epidural Clonipres is administered only by trained healthcare professionals in a monitored setting. If a dose is missed, take it as soon as remembered unless it is close to the next dose; do not double the dose, and never stop treatment abruptly without medical advice.

Clonipres has the following well-documented, clinically significant interactions:

• Beta-blockers: Concurrent use increases the risk of severe rebound hypertension if Clonipres is discontinued abruptly. When both are used and need to be stopped, the beta-blocker should be withdrawn several days before Clonipres is gradually tapered.
• CNS depressants (opioids, benzodiazepines, sedatives, alcohol): Additive sedation and CNS depression may occur; combinations should be used cautiously.
• Other bradycardia-causing or AV-nodal blocking agents (e.g., digoxin, verapamil, diltiazem): Additive risk of bradycardia and AV conduction block.
• Tricyclic antidepressants: May blunt the antihypertensive effect of Clonipres.
• Other antihypertensive agents: Additive blood-pressure-lowering effect; may require dose adjustment to avoid hypotension.

Common side effects of Clonipres are dose-related and include:

• Dry mouth (very common)
• Drowsiness/sedation and fatigue
• Dizziness and headache
• Constipation
• Orthostatic hypotension

Less common but clinically important effects include bradycardia, AV conduction abnormalities, mood changes/depression, sexual dysfunction, and skin reactions at transdermal patch sites. Most side effects diminish with continued use or dose adjustment; a healthcare provider should be informed of persistent or bothersome symptoms.

Clonipres crosses the placenta, and data in pregnant women are limited. Clonipres should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; use only if clearly needed and under close medical supervision. Clonipres is excreted in breast milk; caution is advised, and a physician should be consulted to weigh the benefits of treatment against potential effects on the nursing infant before use during breastfeeding.

Do not stop abruptly: Sudden discontinuation of Clonipres can cause a rapid rise in blood pressure (rebound hypertension), which may be severe and, rarely, life-threatening, sometimes accompanied by symptoms such as agitation, headache, tremor, and rebound sympathetic overactivity. Clonipres must always be tapered gradually under medical supervision. This risk is heightened in patients also taking a beta-blocker; in this situation, the beta-blocker should be withdrawn first, several days before Clonipres is slowly tapered, to avoid unopposed alpha-adrenergic rebound (see Interactions).

Sedation: Clonipres commonly causes drowsiness and dry mouth; patients should use caution when driving or operating machinery until they know how it affects them, and avoid alcohol or other sedating substances (see Interactions).

Cardiac conduction: Use with caution in patients with bradycardia, AV conduction abnormalities, or those on other AV-nodal blocking drugs, due to additive risk (see Interactions).

Depression: Clonipres may worsen pre-existing depression; monitor patients with a history of depression closely.

Renal impairment: Dose adjustment is required due to reduced clearance (see Dosage and Administration and Use in Special Populations).

Patients should not stop, skip, or change their dose of Clonipres without consulting their physician.

Overdose with Clonipres can cause an initial transient rise in blood pressure followed by hypotension, bradycardia, respiratory depression, marked drowsiness or reduced consciousness, hypothermia, and pinpoint pupils; severe overdose can resemble opioid toxicity and may be life-threatening, particularly in children. If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is supportive and should only be provided in a medical facility; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Clonipres is partly eliminated by the kidneys; patients with moderate-to-severe renal impairment may need lower doses and longer intervals between doses, with close monitoring (see Dosage and Administration).

Hepatic impairment: Use with caution; no formal dosing guidelines are established.

Elderly: Older adults may be more sensitive to the hypotensive and sedative effects of Clonipres; start at the lower end of the dosing range and titrate cautiously.

Children: See Pediatric Uses for age-specific approved use and dosing.

For hypertension and ADHD, Clonipres is typically used long-term as part of chronic disease management, with periodic clinical review to confirm continued benefit and tolerability. For short-term uses such as management of withdrawal symptoms, treatment is usually limited to the period of acute symptoms under medical supervision. Regardless of indication, Clonipres must always be discontinued by gradual tapering rather than stopped abruptly (see Precautions and Warnings).

Antihypertensives; Centrally-acting alpha-2 adrenergic agonists

Clonidine Hydrochloride stimulates alpha-2 adrenergic receptors in the brainstem (vasomotor centers), reducing sympathetic nervous system outflow. This decreases peripheral vascular resistance, renal vascular resistance, heart rate, and blood pressure, and also dampens central noradrenergic activity relevant to attention regulation (ADHD) and to sympathetic hyperarousal seen in withdrawal states.

C

Extended-release oral Clonipres is approved for ADHD in children and adolescents aged 6–17 years, used as monotherapy or as an adjunct to stimulant medication, with weight/age-based titration starting at 0.1 mg at bedtime up to a maximum of 0.4 mg/day. Use of Clonipres for hypertension in children is generally off-label, with dosing individualized by a specialist. Safety and efficacy of Clonipres have not been established in children younger than 6 years for ADHD, and pediatric use for any indication should be supervised closely by a physician, given the risk of sedation and hemodynamic effects.